Vivos Therapeutics acquires equity in SOD Sciences and co-ownership of a chronic disease test, enhancing its market presence.
Transaction Expected to Add More Than $10 Million to Stockholders' Equity as Vivos Forms Strategic Alliances Offering Potential New Revenue and Profit OpportunitiesLITTLETON, Colo., Oct. 19, 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results